Burstein HJ et al. Clinical activity of trastuzumab and vinorelbine in women with HER2- overexpressing metastatic breast cancer. J Clin Oncol 2001;19(10):2722-30. Abstract.

Christodoulou C et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. Anticancer Res 2003;23(1B):737-44. Abstract.

Cobleigh MA et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639-48. Abstract.

Jahanzeb M et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002;7(5):410-7. Abstract.

Miller KD et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2001;15(2 Suppl 3):38-40. Abstract.

Montemurro F et al. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: A pilot phase II study. Am J Clin Oncol 2003;26(1):95-7. Abstract.

O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2003;30(2 Suppl 3):22-6. Abstract.

Seidman AD et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19(10):2587-95. Abstract.

Yardley DA et al. Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res Treat 2002;Abstract 439. Abstract.